{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:42:16Z","timestamp":1791333736592,"version":"4.3.1"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.2215\/cjn.07821109","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T22:45:02Z","timestamp":1265928302000},"page":"531-548","source":"Crossref","is-referenced-by-count":222,"title":["Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors"],"prefix":"10.2215","volume":"5","author":[{"given":"Matthew R.","family":"Weir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20230601","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinte.1987.00370050063011","article-title":"Hyperkalemia as a complication of drug therapy","volume":"147","author":"Rimmer","year":"1987","journal-title":"Arch Intern Med"},{"key":"R2-21-20230601","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","article-title":"Analysis of factors causing hyperkalemia","volume":"46","author":"Takaichi","year":"2007","journal-title":"Intern Med"},{"key":"R3-21-20230601","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(08)61212-X","article-title":"Renin-angiotensin blockade and kidney disease","volume":"372","author":"Sarafidis","year":"2008","journal-title":"Lancet"},{"key":"R4-21-20230601","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archinte.158.8.917","article-title":"Hyperkalemia in hospitalized patients: Causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines","volume":"158","author":"Acker","year":"1998","journal-title":"Arch Intern Med"},{"key":"R5-21-20230601","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.1993.293","article-title":"Renal complications of nonsteroidal anti-inflammatory drugs","volume":"44","author":"Schlondorff","year":"1993","journal-title":"Kidney Int"},{"key":"R6-21-20230601","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00002060-200001000-00019","article-title":"Heparin-induced hyperkalemia confirmed by drug rechallenge","volume":"79","author":"Orlando","year":"2000","journal-title":"Am J Phys Med Rehabil"},{"key":"R7-21-20230601","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002018-199921060-00004","article-title":"Immunosuppressant-induced nephropathy: Pathophysiology, incidence and management","volume":"21","author":"Olyaei","year":"1999","journal-title":"Drug Saf"},{"key":"R8-21-20230601","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/bmj.286.6372.1189","article-title":"Hyperkalaemia in patients in hospital","volume":"286","author":"Paice","year":"1983","journal-title":"BMJ (Clin Res Ed"},{"key":"R9-21-20230601","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R10-21-20230601","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R11-21-20230601","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1995.tb04482.x","article-title":"Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients","volume":"39","author":"Fogari","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"R12-21-20230601","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"R13-21-20230601","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0002-9149(99)80413-5","article-title":"Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension","volume":"75","author":"Goldberg","year":"1995","journal-title":"Am J Cardiol"},{"key":"R14-21-20230601","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/00004872-200106001-00006","article-title":"Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist","volume":"19","author":"Puchler","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"R15-21-20230601","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0149-2918(01)80072-2","article-title":"Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial","volume":"23","author":"McGill","year":"2001","journal-title":"Clin Ther"},{"key":"R16-21-20230601","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the anti-hypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-21-20230601","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"R18-21-20230601","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","article-title":"Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis","volume":"1","author":"Weir","year":"2007","journal-title":"J Am Soc Hypertens"},{"key":"R19-21-20230601","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"R20-21-20230601","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R22-21-20230601","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"R23-21-20230601","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R24-21-20230601","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R25-21-20230601","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-21-20230601","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"R27-21-20230601","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R28-21-20230601","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"R29-21-20230601","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R30-21-20230601","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1524-6175.2004.03511.x","article-title":"Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: The AMAZE trials","volume":"6","author":"Izzo","year":"2004","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R31-21-20230601","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"R32-21-20230601","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"R33-21-20230601","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R34-21-20230601","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R35-21-20230601","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R36-21-20230601","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.99.20.2658","article-title":"Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group","volume":"99","author":"Baruch","year":"1999","journal-title":"Circulation"},{"key":"R37-21-20230601","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R38-21-20230601","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R39-21-20230601","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"R40-21-20230601","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"R41-21-20230601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R42-21-20230601","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabet Med"},{"key":"R43-21-20230601","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"R44-21-20230601","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"R45-21-20230601","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R46-21-20230601","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"R47-21-20230601","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"R48-21-20230601","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R49-21-20230601","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"key":"R50-21-20230601","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R51-21-20230601","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1525-139X.2001.00087.x","article-title":"Hyperkalemia in dialysis patients","volume":"14","author":"Ahmed","year":"2001","journal-title":"Semin Dial"},{"key":"R52-21-20230601","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-138-11-200306030-00013","article-title":"Pharmacotherapy for heart failure in patients with renal insufficiency","volume":"138","author":"Shlipak","year":"2003","journal-title":"Ann Intern Med"},{"key":"R53-21-20230601","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0891-6632(90)90057-C","article-title":"Hyperkalemia in diabetes mellitus","volume":"4","author":"Uribarri","year":"1990","journal-title":"J Diabet Complications"},{"key":"R54-21-20230601","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/CIRCULATIONAHA.108.807917","article-title":"Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: Balancing risk and benefit","volume":"118","author":"Desai","year":"2008","journal-title":"Circulation"},{"key":"R55-21-20230601","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R56-21-20230601","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pds.1217","article-title":"Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers","volume":"16","author":"Raebel","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R57-21-20230601","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/clinchem\/46.2.306","article-title":"Hemolyzed specimens: A reason for rejection or a clinical challenge?","volume":"46","author":"Carraro","year":"2000","journal-title":"Clin Chem"},{"key":"R58-21-20230601","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1515\/CCLM.2006.054","article-title":"Influence of hemolysis on routine clinical chemistry testing","volume":"44","author":"Lippi","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"R59-21-20230601","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201003000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:29Z","timestamp":1786369169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201003000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.07821109","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}